BioCentury
ARTICLE | Finance

Highlights of weekly biotech stock moves

Regulatory, clinical and other milestones

October 28, 2013 7:00 AM UTC

Actelion Ltd. (SIX:ATLN) was off CHF0.20 to CHF69.15 on Friday after EMA's CHMP backed approval of Opsumit macitentan for pulmonary arterial hypertension (PAH).

Actelion gained CHF4.55 on the week. The move included a bump from the post-market FDA approval of Opsumit for PAH on Oct. 18. The biotech plans to launch Opsumit in the U.S. next month...